UCB’s Vimpat (lacosamide) Receives CHMP’s Positive Opinion for Primary Generalized Tonic-Clonic Seizures

Shots: The EMA’s CHMP has adopted a positive opinion on a license extension for Vimpat (lacosamide) and Lacosamide UCB (lacosamide) as an adjunctive therapy in the treatment for PGTCS in adults, adolescents, and children from 4 years of age with idiopathic generalized epilepsy The CHMP’s positive opinion is based on P-lll study assessing lacosamide as …

UCB’s Vimpat (lacosamide) Receives CHMP’s Positive Opinion for Primary Generalized Tonic-Clonic Seizures Read More »